share_log

BRIEF-AIM Immunotech Submits IND And Accompanying Fast Track Application For Phase 2 Trial Of Ampligen In Patients With Locally Advanced Or Metastatic Late-Stage Pancreatic Cancer

BRIEF-AIM Immunotech Submits IND And Accompanying Fast Track Application For Phase 2 Trial Of Ampligen In Patients With Locally Advanced Or Metastatic Late-Stage Pancreatic Cancer

Brief-AIM免疫技術提交Ind和伴隨的Fast Track應用於局部晚期或轉移性晚期胰腺癌患者的Ampligen第2期試驗
reuters ·  2021/10/19 07:25

Oct 19 (Reuters) - AIM ImmunoTech Inc AIM.A :

路透10月19日電-AIM Immunotech Inc AIM.A:

* AIM IMMUNOTECH SUBMITS IND AND ACCOMPANYING FAST TRACK APPLICATION FOR PHASE 2 TRIAL OF AMPLIGEN IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC LATE-STAGE PANCREATIC CANCER

*AIM Immunotech提交Ind和隨附的Fast Track申請,用於局部晚期或轉移性晚期胰腺癌患者的Ampligen第2期試驗

Source text for Eikon: ID:nGNEMYnyj Further company coverage: AIM.A

Eikon的源文本:ID:nGNEMYnyj進一步的公司報道:AIM.A

((reuters.briefs@thomsonreuters.com;))

(reurs.Briefs@thomsonreurs.com;)

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論